Skip to main content
TipRanks
Go Ultimate75% OFF

BioGend Therapeutics Co., Ltd. (6733) Cash flow

BioGend Therapeutics Co., Ltd. Cash Flow

TW:6733's free cash flow for Q2 2026 was NT$-12.04M. For the 2026 fiscal year, TW:6733's free cash flow was decreased by NT$-1.07M and operating cash flow was NT$-10.97M. See a summary of the company’s cash flow.

Cash Flow
Cash FlowDec 25Dec 24Dec 23Dec 22Dec 21
NT$ -63.66MNT$ -98.91MNT$ -138.72MNT$ -168.78MNT$ -136.80M
NT$ 66.43MNT$ -8.20MNT$ -89.64MNT$ 201.70MNT$ -134.27M
NT$ -3.70MNT$ -3.64MNT$ 396.42MNT$ -4.81MNT$ 287.85M
NT$ 217.90MNT$ 219.02MNT$ 330.51MNT$ 163.64MNT$ 136.32M
NT$ -65.52MNT$ -99.56MNT$ -164.76MNT$ -186.96MNT$ -137.47M

Currency in TWD

BioGend Therapeutics Co., Ltd. Cash Flow

-400M-200M0200M400M600M2019202020212022202320242025OperatingInvestingFinancing